放疗、替莫唑胺与抗PD-1治疗对实验性高级别胶质瘤免疫微环境的调控
该研究在小鼠神经球/CT-2A高级别胶质瘤模型中,分析放疗、替莫唑胺和抗PD-1单药或联合治疗对生存、肿瘤体积及肿瘤浸润免疫细胞的影响。结果显示放疗增加总T细胞和CD8+ T细胞并减少M2型巨噬细胞/小胶质细胞和mMDSC,而放疗联合替莫唑胺诱导强烈免疫抑制且抗PD-1无法有效逆转。
要点
- 放疗增加CD8+ T细胞并减少M2型巨噬细胞和mMDSC。
- 替莫唑胺或抗PD-1单药对淋巴细胞亚群影响与对照相当。
- 放疗联合替莫唑胺降低CD8+ T细胞,抗PD-1仅部分缓解。
核心结论
- 放疗、替莫唑胺和抗PD-1均改变高级别胶质瘤免疫微环境。
- 放疗联合替莫唑胺诱导强烈免疫抑制,抗PD-1不能有效抵消。
研究设计与样本
- 小鼠神经球/CT-2A高级别胶质瘤模型。
- 放疗4 Gy单次、替莫唑胺50 mg/kg共4次、抗PD-1 100 μg共3次,单用或联合。
- 分析生存、肿瘤体积和肿瘤浸润免疫细胞。
主要发现
- 放疗较替莫唑胺增加总T细胞(P = .0159)和CD8+ T细胞(P = .0078)。
- 替莫唑胺或抗PD-1组淋巴细胞亚群与对照相当。
- 放疗较对照减少M2肿瘤相关巨噬细胞/小胶质细胞(P = .0019)和mMDSC(P = .0003)。
- 替莫唑胺和抗PD-1也减少mMDSC但较弱(P = .0439和P = .0538)。
- 放疗联合替莫唑胺较单放疗降低CD8+ T细胞(P = .0145),加抗PD-1提高CD8+ T/Treg比值但未达统计学显著(P = .0973)。
临床怎么用
- 实验提示放疗与替莫唑胺联合可能削弱CD8+ T细胞介导的免疫反应。
- 抗PD-1联合放化疗的免疫协同需进一步优化策略。
局限性
- 改变放疗、替莫唑胺和抗PD-1联合顺序未影响生存或免疫效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The lack of immune synergy with conventional chemoradiation could explain the failure of checkpoint inhibitors in current clinical trials for high-grade gliomas (HGGs). OBJECTIVE: To analyze the impact of radiotherapy (RT), Temozolomide (TMZ) and antiprogrammed cell death protein 1 (αPD1) (as single or combined treatments) on the immune microenvironment of experimental HGGs. METHODS: Mice harboring neurosphere /CT-2A HGGs received RT (4 Gy, single dose), TMZ (50 mg/kg, 4 doses) and αPD1 (100 μg, 3 doses) as monotherapies or combinations. The influence on survival, tumor volume, and tumor-infiltrating immune cells was analyzed. RESULTS: RT increased total T cells (P = .0159) and cluster of differentiation (CD)8+ T cells (P = .0078) compared to TMZ. Lymphocyte subpopulations resulting from TMZ or αPD1 treatment were comparable with those of controls. RT reduced M2 tumor-associated macrophages/microglia (P = .0019) and monocytic myeloid derived suppressor cells (mMDSCs, P = .0003) compared to controls. The effect on mMDSC was also seen following TMZ and αPD1 treatment, although less pronounced (P = .0439 and P = .0538, respectively). Combining RT with TMZ reduced CD8+ T cells (P = .0145) compared to RT alone. Adding αPD1 partially mitigated this effect as shown by the increased CD8+ T cells/Tregs ratio, even if this result failed to reach statistical significance (P = .0973). Changing the combination sequence of RT, TMZ, and αPD1 did not alter survival nor the immune effects. CONCLUSION: RT, TMZ, and αPD1 modify the immune microenvironment of HGG. The combination of RT with TMZ induces a strong immune suppression which cannot be effectively counteracted by αPD1.
引用
- Riva M, Wouters R, Sterpin E, et al. Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma. Neurosurgery. 2021. PMID: 33289503. doi:10.1093/neuros/nyaa421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。